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Human kallikrein 6 protein is a newly discovered human kallikrein. We determined the amount of human kallikrein 6 in
extracts of 182 ovarian tumours and correlated speciﬁc activity (ng hK6 mg
71 total protein) with clinicopathological variables
documented at the time of surgical excision and with outcome (progression free survival, overall survival) monitored over a
median interval of 62 months. Thirty per cent of the tumours were positive for human kallikrein 6 (435 ng hK6 mg
71 total
protein). Human kallikrein 6-speciﬁc immunohistochemical staining of four ovarian tissues that included benign, borderline and
malignant lesions indicated a cytoplasmic location of human kallikrein 6 in tumour cells of epithelial origin, although the
intensity of staining was variable. Tumour human kallikrein 6 (ng hK6 mg
71 total protein) was higher in late stage disease,
serous histotype, residual tumour 41 cm and suboptimal debulking (41 cm) (P50.05). Univariate analysis revealed that
patients with tumour human kallikrein 6 positive speciﬁc activity were more likely to suffer progressive disease and to die
(hazard ratio 1.71 (P=0.015) and 1.88 (P=0.022), respectively). Survival curves demonstrated the same (P=0.013 and 0.019,
respectively). Multivariate analysis revealed that human kallikrein 6 positivity was retained as an independent prognostic
variable in several subgroups of patients, namely those with (low) grade I and II tumours (hazard ratio progression free survival
4.3 (P=0.027) and overall survival 4.1 (P=0.023)) and those with optimal debulking (hazard ratio progression free survival 3.8
(P=0.019) and overall survival 5.6 (P=0.011)). We conclude that tumour kallikrein 6 protein levels have utility as an
independent adverse prognostic marker in a subgroup of ovarian cancer patients with otherwise apparently good prognosis.
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Human kallikrein 6 protein (hK6) is one of the newly discovered
members of the human kallikrein gene family, a subgroup of 15
serine proteases mapping in tandem to chromosome 19q 13.3–
13.4 (Diamandis et al, 2000a; Yousef and Diamandis, 2001).
Previously called zyme (Little et al, 1997), protease M (Anisowicz
et al, 1996), and neurosin (Yamashiro et al, 1997), kallikrein 6 is
now the accepted name (Diamandis et al, 2000b). hK6 is a tryp-
sin-like serine protease of unknown physiologic function that is
secreted as a 223 amino acid protein. hK6 has been found in various
biological ﬂuids including milk from lactating women, nipple aspi-
rate ﬂuid, breast cyst ﬂuid, male and female serum, seminal plasma,
and amniotic ﬂuid (Diamandis et al, 2000c). Various tissues express
the hK6 gene and synthesize the protein (Diamandis et al, 2000c;
Yousef et al, 1999). Expression is particularly prominent in the brain
(Yamashiro et al, 1997), and this, along with the amyloidogenic
potential of hK6 (Little et al, 1997) has raised the possibility of a
role for hK6 in amyloid precursor processing and the development
of Alzheimer’s disease. Recently, Diamandis et al (2000d) have
shown that hK6 is elevated in the cerebrospinal ﬂuid and blood
of individuals with histologically conﬁrmed Alzheimer’s, thereby
suggesting hK6 may be of value in the diagnosis of this disorder.
The newly identiﬁed members of the kallikrein family are being
intensively investigated for their utility as cancer biomarkers, in
part because other previously identiﬁed members, namely prostate
speciﬁc antigen (human kallikrein 3) (Diamandis, 1999) and
human glandular kallikrein 2 (Rittenhouse et al, 1998), have been
found to be particularly useful in this regard and in part because it
is reasonable to postulate on biological grounds that proteases are
important mediators of tumour invasion and metastasis (Wood-
house et al, 1997; Kleiner and Stetler-Stevenson, 1999; Matrisian,
1999). Investigations are proceeding as sensitive and speciﬁc assays
measuring the gene expression or protein mass of each newly iden-
tiﬁed member of the kallikrein family become available. Tissue
expression of the kallikreins examined to date appears to be
down-regulated in aggressive forms of breast cancer (hK3 (PSA)
(Levesque et al, 1998), hK10 (Liu et al, 1996; Goyal et al, 1998),
hK13 (Yousef et al, 2000) and hK6 (Anisowicz et al, 1996)) and
up-regulated in ovarian cancer (hK4 (Obiezu et al, 2002), hK10
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Ovarian cancer is the disease that causes more deaths than any
other cancer of the female reproductive system (Riman et al, 1998).
Current serological markers such as CA125 (Maggino and Gadducci,
2000) and inhibin (Lambet-Messerlian, 2000) have not gained wide
clinical acceptance for early diagnosis, and there is continued inter-
est in identifying biomarkers that would facilitate diagnosis of
ovarian carcinoma in its early stages or provide insight regarding
prognosis of established disease (Menon and Jacobs, 2000). Two
recently published studies (Diamandis et al, 2000e; Tanimoto et
al, 2001) have found initial evidence that hK6 may have clinical
utility in ovarian cancer. Data from the former group show that
signiﬁcant elevation of hK6 concentration in the serum occurs
almost exclusively in individuals with ovarian cancer. Speciﬁcally,
they found that 66% of 80 individuals with widespread ovarian
cancer had serum hK6 in excess of 15 mgl
71 while only two out
of 217 individuals with a wide array of other malignancies with
high tumour burden had the same. Serum hK6 concentration
correlated poorly with that of CA125 in the individuals with ovar-
ian cancer. The data from Tanimoto et al (2001) show that there is
increased expression of hK6 transcripts in ovarian tumours. Using
quantitative PCR, they screened 44 ovarian tumours and 10 normal
ovaries and found that kallilkrein 6 mRNA expression was signiﬁ-
cantly elevated in the majority of low grade and high grade
tumours, but not in normal ovary. These two recent studies have
unequivocally established that there is increased expression of
hK6 in ovarian cancer, but the prognostic signiﬁcance of this
expression remains unknown. To examine this question, we have
determined the amount of hK6 protein per milligram total protein
in extracts of 180 ovarian tumours and correlated this with clinico-
pathological variables documented at the time of surgical excision
and with progression free survival and overall survival. We report
the ﬁndings of this study here along with the immunohistochem-
ical localisation of hK6 in four ovarian neoplasms of varying cell
type and malignant potential.
MATERIALS AND METHODS
Ovarian cancer patients
One hundred and eighty patients with primary ovarian cancer were
included in this study. These patients underwent surgery for ovar-
ian cancer at the Department of Gynecology, University of Turin,
Italy. Patient age ranged from 25 to 82 years with a median of
59 years. Clinical and pathological information documented at
the time of surgery included clinical stage of the cancer, grade
and histology of the tumour, and amount of remaining tumour.
Menopausal status was documented and response to chemotherapy
monitored. Tumours were staged according to the International
Federation of Gynaecology and Obstetrics (FIGO) criteria. Histolo-
gic classiﬁcation was based on the World Health Organization and
FIGO recommendations. Of the tumours included in this study, 80
were classiﬁed as serous papillary, 32 as undifferentiated, 27 as
endometrioid, 13 as mucinous, 14 as clear cell, 10 as mullerian
and four as other. The size of the residual tumours ranged from
0 to 9 cm, with a median of 1.1 cm.
Patients were monitored for survival and disease progression (no
apparent progression or progression) for a median duration of 62
months (range 1–99 months). Follow-up information was avail-
able for 165 of the patients. Ninety-seven (54%) of these
relapsed and 61 (34%) died during the course of the follow-up
period.
Investigations were carried out in accordance with the ethical
standards of the Helsinki Declaration of 1975, as revised in 1983,
and were approved by the Institute of Obstetrics and Gynecology,
Turin, Italy.
Preparation of tumour cell extracts
Tumour tissue was frozen in liquid nitrogen immediately after
surgery and stored at 7808C until extraction. Twenty to 100 mg
of frozen tissue was pulverized on dry ice to a ﬁne powder and
added to 10 volumes of extraction buffer (50 mM Tris, pH 8.0,
150 mM NaCl, 5 mM EDTA, 10 g l
71 of NP-40 surfactant, 1 mM
phenylmethyl sulphonyl ﬂuoride, 1 g l
71 of aprotinin, 1 g l
71 of
leupeptin). The resulting suspension was incubated on ice for
30 min during which time it was vortexed every 10 min. The
mixture was then centrifuged at 14000 r.p.m. at 48C for 30 min
and the supernatant (cell extract) was collected and stored at
7808C until analysis. Protein concentration of the extract was
determined with the bicinchoninic acid method, with albumin as
standard (Pierce Chemical Co., Rockford, IL, USA).
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Figure 1 (A) Frequency distribution of hK6 speciﬁc activity in ovarian tu-
mour extracts. (B) Plot of hK6 tumour speciﬁc activity vs Chi-square statis-
tic to determine the limit between hK6 positive and hK6 negative tumours
that is most predictive of overall survival.
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The concentration of hK6 in tumour cell extract was quantiﬁed
with a highly sensitive and speciﬁc non-competitive immunoassay
for hK6 that has been previously described and evaluated in detail
(Diamandis et al, 2000c). The assay incorporated two hK6-speciﬁc
polyclonal antibodies, one raised in mouse and the other in rabbit,
in a sequential two site immunometric format with time resolved
ﬂuorescence detection. Analysis of standards, tumour cell extracts
and control pools was carried out in duplicate in 96-well polystyr-
ene microtiter plates with 200 ml of specimen added to the
immunoassay. The standard curve using recombinant hK6 protein
ranged from 0.5 mgl
71 to 200 mgl
71. Assay precision was better
than 10%. Signal detection and data reduction were performed
automatically by the CyberFluor 615 Immunoanalyzer.
Localisation of hK6 in ovarian tumour specimens by
immunohistochemistry
A rabbit polyclonal antibody was raised against hK6 full-size
recombinant protein, produced in yeast cells. Immunohistochem-
ical staining for hK6 was performed according to a standard
immunoperoxidase method. Brieﬂy, parafﬁn-embedded tissue
sections (4 mm) were ﬁxed and dewaxed. Endogenous peroxidase
activity was blocked with 3% aqueous hydrogen peroxide for
15 min. Sections were then treated with 0.4% pepsin at pH 2.0
for 5 min at 428C and blocked with 20% protein blocker (Signet
Labs) for 10 min. The primary antibody was then added at
1:400 dilution for 1 h at room temperature. After washing, bioti-
nylated anti-rabbit antibody (Signet) was added, diluted four-fold
in antibody dilution buffer (DAKO). Following incubation and
washing, streptavidin tagged horseradish peroxidase was added
for 30 min at room temperature. After washing, detection was
achieved with amino ethyl carbazole (AEC) for 5–10 min. The
slides were counterstained with haematoxylin and then mounted
with cover slips.
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Figure 2 Comparison of hK6 concentration in extracts from normal
ovarian tissues (‘normal’), ovarian tissues with benign disease (‘benign’),
and ovarian cancer (‘cancer’). n indicates the number of specimens in each
group. Horizontal bars represent the median hK6 speciﬁc activity in each
group.
Table 1 Relationship between hK6 status and other variables in 180
ovarian cancer patients
No. of patients (%)
Variable Patients hK6 negative hK6 positive P value
Stage
I 44 38 (86.4) 6 (13.6)
II 13 8 (61.5) 5 (38.5) 0.034
a
III 110 72 (65.4) 38 (34.5)
IV 13 7 (53.8) 6 (46.2)
Grade
G1 25 21 (84.0) 4 (16.0)
G2 27 21 (77.8) 6 (22.2) 0.33
a
G3 119 84 (70.6) 35 (29.4)
x9
Histotype
Serous 80 52 (65.0) 28 (35.0)
Undifferentiated 27 17 (63.0) 10 (37.0)
Endometrioid 32 27 (46.7) 5 (53.3)
Mucinous 13 10 (76.9) 3 (13.1) 0.31
b
Clear cell 14 11 (78.6) 3 (21.4)
Mullerian 10 8 (80.0) 2 (20.0)
Others 4 3 (75.0) 1 (25.0)
Residual tumour (cm)
0 80 67 (83.2) 13 (16.3)
1–2 29 16 (55.2) 13 (44.8) 0.002
a
42 64 40 (62.5) 24 (37.5)
x7
Menopause
Pre/peri 50 32 (64.0) 18 (36.0) 0.075
b
Post 130 99 (76.2) 31 (23.8)
Response to CTX
c
NC/PD 15 11 (73.3) 4 (26.7) 0.99
b
CR/PR 148 104 (70.3) 44 (29.7)
NE 17
aw
2 test.
b Fisher’s Exact Test.
cCTX; chemotherapy, NC; no change, PD; progressive
disease, CR; complete response, PR; partial response, NE; not evaluated. x. Status
unknown.
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Figure 3 Distribution of hK6 speciﬁc activity (ng hK6 mg
71 total
protein) in tumour extracts from stage I–II and stage III–IV ovarian cancer
patients. n indicates the number of tumours comprising each group.
Horizontal bars represent the median value of hK6 tumour speciﬁc activity.
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Statistical analysis was performed with SPSS software (SPSS Inc.
Richmond, CA, USA). To analyse data, patients were divided
into different groups according to clinical and pathological para-
meters. Because the distribution of hK6 mass per mg total
protein (i.e. speciﬁc activity) in the ovarian tumour extracts
was not Gaussian, the nonparametric Mann-Whitney U-test
was used to determine differences between two groups and the
nonparametric Kruskal–Wallis test was used for the analysis of
differences among more than two groups. These tests treated
hK6 speciﬁc activity in the tumour extract (ng hK6 mg
71 total
protein) as a continuous variable. hK6 tumour extract speciﬁc
activity was also classiﬁed as either hK6-positive (435 ng mg
71
total protein; see Figure 1B for explanation) or hK6-negative
(435 ng mg
71 total protein). The relationship of this dichoto-
mous variable to other clinicopathological correlates was
established with the Chi Square (w
2) test or the Fisher’s Exact
Test, as appropriate. The impact of tumour extract hK6 speciﬁc
activity on patient survival and on progression of the disease
(progression-free survival) was assessed with the hazards ratio
calculated by both univariate and multivariate Cox proportional
hazards regression models (Cox, 1972). In the multivariate analy-
sis, the clinical and pathological variables that may affect
survival, including stage of disease, tumour grade, residual
tumour, histologic type and age were adjusted. Kaplan–Meier
progression-free survival and overall survival curves (Kaplan
and Meier, 1958) were constructed to demonstrate the survival
differences between the hK6-positive and hK6-negative patients.
The log rank test (Mantel, 1966) was used to examine the signif-
icance of the differences among the survival curves. Following
analysis of the entire patient data set as a whole, the process
was repeated on subgroups stratiﬁed separately by disease stage,
by tumour grade and by amount of tumour remaining following
surgery (debulking success). The impact of tumour hK6 level
(positive or negative) on survival and on disease progression
was determined by univariate and multivariate models for each
of the subgroups.
RESULTS
Distribution of hK6 speciﬁc activity in ovarian tumour
extracts
The distribution of hK6 speciﬁc activity in ovarian tumour extracts
from the 180 patients (Figure 1A) ranged from 0.04 ng mg
71 total
protein to 497 ng mg
71 of total protein with a mean of
33 ng mg
71 total protein and a median of 13.2 ng mg
71 total
protein. A value of 35 ng mg
71 total protein was identiﬁed by
Chi square analysis (w
2=7.3; P=0.007) as the optimal cutpoint to
distinguish positive from negative tumours in terms of predicting
overall survival (Figure 1B). Thirty per cent of the tumours were
hK6 positive by this criterion. hK6 speciﬁc activity in tumour
extracts was treated both as a continuous variable and as a
dichotomous variable (435 ng mg
71 total protein=negative,
435 ng mg
71 total protein=positive) in the analyses that follow.
hK6 speciﬁc activity (ng hK6 mg
71 total protein) was signiﬁ-
cantly elevated (P50.001 by the Kruskal–Wallis test) in extracts
of ovarian tumour (mean 32.7, standard error 3.8, range 0.04 to
497) compared to extracts prepared from normal ovarian tissues
(mean 3.5, standard error 2.5, range 0.05 to 20.8) or from ovarian
tissue with benign disease (mean 3.2, standard error 2.6, range 0.03
to 21.5) (Figure 2). Further analysis showed there was no signiﬁ-
cant difference in hK6 speciﬁc activity among the ovarian
tumours when they were stratiﬁed by histotype (i.e. serous vs
undifferentiated vs endometrioid, etc) (data not shown).
Relationships between hK6 status and other
clinicopathological variables
The distributions of various clinicopathological variables between
hK6-positive and hK6-negative patients are summarized in Table
1. The relationships between hK6 status and these variables were
examined with either the w
2 Test or Fisher’s Exact Test, as appro-
priate. No relationship was observed between hK6 status and
tumour grade, menopausal status and response to chemotherapy.
However, hK6-positive patients were more likely to have advanced
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Table 2 Univariate and multivariate analysis of prognostic value of hK6
Progression-free survival (PFS) Overall survival (OS)
Variable HR
a 95% CI
b P value HR
a 95% CI
b P value
Univariate Analysis
HK6
Negative 1.00 1.00
Positive 1.71 1.11–2.64 0.015 1.88 1.09–3.21 0.022
As a continuous variable 1.005 1.002–1.007 0.001 1.004 0.999–1.008 0.074
Stage of disease (ordinal) 2.79 2.07–3.79 50.001 3.07 2.05–4.61 50.001
Grading (ordinal) 1.95 1.38–2.75 50.001 2.07 1.31–3.29 0.002
Residual tumour (ordinal) 1.27 1.20–1.34 50.001 1.31 1.22–1.41 50.001
Histologic type
c 0.83 0.68–1.00 0.055 0.88 0.69–1.13 0.34
Age 1.012 0.99–1.03 0.14 1.015 0.99–1.03 0.15
Multivariate Analysis
HK6
Negative 1.00 1.00
Positive 1.40 0.84–2.32 0.19 1.08 0.79–1.49 0.62
As a continuous variable 1.002 0.99–1.006 0.22 1.001 0.99–1.004 0.69
Stage of disease (ordinal) 1.57 1.09–2.27 0.014 1.72 1.053–2.82 0.03
Grading (ordinal) 1.31 0.84–2.32 0.18 1.31 0.75–2.25 0.33
Residual tumour (ordinal) 1.14 1.05–1.24 0.001 1.21 1.09–1.34 50.001
Histologic type
c 0.95 0.82–1.11 0.57 1.04 0.86–1.26 0.68
Age 1.02 0.99–1.039 0.12 1.02 0.99–1.04 0.21
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConﬁdence interval of the estimated HR.
cSerous vs others.
Prognostic significance of tumour hK6 in ovarian cancer
BR Hoffman et al
766
British Journal of Cancer (2002) 87(7), 763–771 ã 2002 Cancer Research UKdisease (stage II–IV), serous tumour histology and greater residual
tumour (41 cm) (all P50.05). hK6 tumour extract speciﬁc activ-
ity when treated as a continuous variable also associated
proportionally with stage of the disease. Figure 3 shows the distri-
bution of hK6 speciﬁc activity stratiﬁed by disease stage. hK6
speciﬁc activity was signiﬁcantly higher in extracts from stage
III–IV ovarian cancer than in those from stage I–II (P=0.002
by the Mann–Whitney U-Test).
Univariate and multivariate survival analysis
The impact of hK6 speciﬁc activity, other clinicopathological vari-
ables and age on disease progression and on overall survival is
presented in Table 2. In univariate analysis, hK6-positive patients
had a signiﬁcantly increased risk of disease progression (hazard
ratio=1.71) and death (hazard ratio=1.88) (P50.05). When hK6
speciﬁc activity was treated as a continuous variable, hazard ratios
were closely similar to those of hK6 negative tumours (arbitrarily
set at 1.00), although the slight increase in risk of disease progres-
sion (hazard ratio=1.005) was highly signiﬁcant at P=0.001.
Kaplan–Meier survival curves demonstrated survival differences
between hK6-positive and hK6-negative patients. As Figure 4
shows, the probability of progression-free and overall survival,
respectively, are lower in hK6-positive patients than in hK6-nega-
tive patients.
The adverse effects of hK6 positivity on progression free
survival and on overall survival were lost in multivariate analy-
sis. As shown in Table 2, when survival outcomes were adjusted
for other clinicopathological variables, hK6-positive and hK6-
negative patients had statistically similar rates of disease progres-
sion and overall survival. Tumour grade also lost its univariate
prognostic signiﬁcance in multivariate analysis. Only stage of
disease and residual tumour remaining after surgery maintained
their independent effects on survival outcome in the multivariate
analysis.
Univariate and multivariate survival analysis in subgroups
of patients
The patients were divided into different subgroups based on
disease stage, tumour grade, and debulking success (residual
tumour). In each subgroup, the impact of hK6 positivity and
negativity on disease progression and on overall survival was
determined by univariate and by multivariate Cox proportional
hazard regression models. The results are shown in Table 3.
hK6 speciﬁc activity (positive, negative) signiﬁcantly impacted
survival in the subgroup of 50 patients with tumour grade I or
II. Univariate analysis revealed that hK6-positive patients were
about nine times more likely to suffer disease progression and ﬁve
times more likely to die than hK6-negative patients. These survi-
val differences remained signiﬁcant even after the data were
subjected to multivariate analysis. The relative risk of both
outcomes arising from hK6 positivity was now about four-fold
(P50.03). hK6 status had no such effect among patients with
Grade III tumour, nor could any discernible effect be demon-
strated among patients with early stage disease and among those
with greater than 1 cm of tumour remaining following surgery.
Univariate analysis revealed a two-fold increase in risk of disease
progression and of death in the subgroup of patients with
advanced disease (stage III and IV) who were hK6 positive, but
the effect was lost in the multivariate analysis. The opposite
occurred in the subset of 80 patients characterised by optimal
debulking of the tumour at the time of surgery (remaining
tumour less than 1 cm in diameter). hK6 positivity had no
demonstrable adverse effect on disease progression or on survival
by univariate analysis, but did become statistically signiﬁcant,
giving a 3.5 and 5.5-fold increase in adverse risk, respectively,
when the data were subjected to multivariate analysis. The emer-
gence of effects in the multivariate model when none are
generated by the univariate model happens when the adjusted
variables have no impact at all on the outcome. In the case here,
this means that stage of disease, tumour grade, tumour histology
and patient age had no prognostic potential on disease progres-
sion and overall survival in this particular subset of patients.
Kaplan–Meier survival curves of the subset of patients with grade
I or II ovarian tumour are shown in Figure 5. As expected from
the univariate analysis mentioned earlier, there was a signiﬁcant
difference in disease progression and survival between hK6 posi-
tive and hK6 negative patients.
Immunohistochemical staining of hK6 in ovarian tumours
Immunohistochemical staining of hK6 in parafﬁn embedded
tumour sections was roughly proportional to hK6 speciﬁc activity
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Figure 4 Kaplan–Meier survival curves of the entire patient population
under study: Effect of hK6 status. (A) Progression-free survival (PFS). (B)
Overall survival (OS). The adverse effect of hK6 positivity on both time
to progression and overall survival was signiﬁcant.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 763–771in tumour extracts (data not shown). Immunohistochemical loca-
lisation of hK6 in ovarian neoplasms of varying malignant
potential, cell type and origin (epithelial vs mesenchymal) is shown
in Figure 6. Strong cytoplasmic staining of many tumour cells, and
absence of any staining of stroma or vessels was observed for the
invasive papillary serous adenocarcinoma, the common malignant
epithelial tumour of the ovary (Figure 6A). The benign, mixed
epithelial and ﬁbrous serous cystadenoﬁbroma presented in Figure
6B stained negligibly in the ﬁbrous component but strongly in the
cytoplasm of the epithelium lining the cysts. Staining was negligible
for the ovarian leiomyoma, a benign smooth muscle tumour, of
Figure 6C, but weakly diffuse throughout the cytoplasm of the
neoplastic epithelium of the mucinous epithelial tumour of low
malignant potential and intermediate grade depicted in Figure
6D. The supporting stroma (far left) of the latter specimen did
not stain. In summary, hK6 staining was restricted to epithelial
cells, being absent in mesenchymal elements including ﬁbrous
supporting stroma. hK6 stained within the cytoplasm of epithelial
cells, but staining intensity was variable among and within tumour
preparations.
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Table 3 Cox proportional hazard regression analysis for subgroups of patients
Progression-free survival Overall survival
Variable HR
a 95% CI
b P value HR
a 95% CI
b P value
Tumor grade I–II
HK6 univariate 9.25 3.33–25.67 50.001 5.05 1.63–15.71 0.005
HK6 multivariate
c 4.29 1.17–15.65 0.027 4.05 1.23–16.6 0.023
Tumor grade III
HK6 univariate 1.45 0.87–2.39 0.14 1.69 0.91–3.14 0.091
HK6 multivariate
c 1.03 0.58–1.83 0.91 1.02 0.48–2.13 0.96
Stage I–II
HK6 univariate 0.90 0.18–4.35 0.89 1.49 0.13–16.53 0.74
HK6 multivariate
d 1.83 0.17–19.41 0.61 2.23 0.20–25.04 0.51
Stage III–IV
HK6 univariate 2.04 1.26–3.29 0.004 1.98 1.12–3.47 0.017
HK6 multivariate
d 1.57 0.93–2.68 0.092 1.33 0.71–2.53 0.37
Optimal debulking success
e
HK6 univariate 1.81 0.72–4.55 0.20 2.61 0.70–9.73 0.15
HK6 multivariate
f 3.75 1.39–10.09 0.019 5.57 1.47–21.04 0.011
Suboptimal debulking success
e
HK6 univariate 1.39 0.83–2.32 0.20 1.16 0.64–2.09 0.62
HK6 multivariate
f 1.27 0.72–2.23 0.40 1.19 0.62–2.27 0.59
aHazard ratio (HR) estimated from Cox proportional hazard regression model.
bConﬁdence interval of the estimated HR.
cMultivariate models were adjusted for stage of disease, residual tumour, histologic type and age.
dMultivariate models were
adjusted for tumour grade, residual tumour, histologic type and age.
eOptimal debulking (0–1 cm residual tumour); suboptimal
debulking (41 cm residual tumour).
fMultivariate models were adjusted for stage of disease, tumour grade, histologic type and
age.
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Figure 5 Effect of hK6 status (positive or negative) on progression-free survival (PFS) and on overall survival (OS) among patients with Grade I and II
ovarian tumour. The adverse effect of hK6 positivity both on time to progression and on overall survival was signiﬁcant (P40.002).
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This is the ﬁrst report of the prognostic signiﬁcance of hK6 in
ovarian cancer. Increased hK6 synthesis was found to be predictive
of more aggressive tumour behaviour over time. Considered apart
from other clinicopathological variables and age, hK6 positivity
across the entire patient population under study was associated
with about a two-fold increase in the risk of both disease progres-
sion and of death. This effect was lost when outcomes were
adjusted for the other clinicopathological variables and age in
multivariate analysis of the entire patient population, but not when
the multivariate analysis was restricted to those patients with lower
grade tumour and with less residual tumour remaining after
surgery (51 cm in diameter). Among the former subgroup of
patients, hK6 positivity predicted about a four-fold increase in
the risk of disease progression and of death (P50.03) while corre-
sponding hazard ratios in the latter subgroup were 3.75 and 5.5,
respectively (P50.02). The data show that hK6 positivity has inde-
pendent predictive potential in these two subgroups and gives
insight into tumour behaviour over time that cannot be gleaned
from the clinical parameters and pathological correlates conven-
tionally measured. Hence hK6 testing could contribute to more
individualized effective treatment of such patients.
In accord with recently published work (Tanimoto et al, 2001),
we found that hK6 is frequently overexpressed in ovarian tumours
compared to nonmalignant ovarian tissue. This overexpression
tended to be higher in tumour from late stage disease than from
early stage disease. Our histochemical studies suggest that hK6 is
synthesized by the epithelial cells of the ovary and is distributed
diffusely within the cytoplasmic compartment.
Epithelial ovarian cancer has one of the worst prognoses among
gynaecologic malignancies, largely because over three-quarters of the
diagnoses are made at a time when the disease has already
established regional or distant metastases (Gatta et al, 1998).
Compounding the problem, tumour progression and aggressiveness
correlate variably with conventional clinical and pathological
markers. Thus there is an important need for additional diagnostic
and prognostic markers for this disease and a number of potential
markers have been identiﬁed. Molecular genetic analysis has uncov-
ered several genes that are altered in a signiﬁcant fraction of ovarian
tumours (Shigemasa et al, 1999; Aunoble et al, 2000) and has iden-
tiﬁed other genes that appear to be involved in tumour progression
(Suzuki et al, 2000). A whole host of serine proteases (Tanimoto et
al, 1997; Hirahara et al, 1998; Underwood et al, 1999; Shigemasa et
al, 2000) in addition to those of the kallikrein family (Tanimoto et
al, 1999; Diamandis et al, 2000a) are overexpressed by epithelial
ovarian tumour cells. These may have prognostic potential insofar
as they assist in degrading the extracellular barriers such as intersti-
tial connective tissue and basement membrane that must be
breached in order for tumour to invade adjacent tissue and metas-
tasize (Duffy, 1992; Aznavoorian et al, 1993). Recently, microarray
based approaches have been used to assemble multigene expression
proﬁles of neoplastic ovarian tissue. Such studies have identiﬁed the
gene coding for HE4, a secreted extracellular protease inhibitor, as a
promising diagnostic marker (Ono et al, 2000) and pinpointed
other genes that correlate with serous and mucinous histology
(Schummer et al, 1999). A recent report (Welsh et al, 2001) analysed
the expression levels of more than 6000 human genes in 27 ovarian
tumours and four normal ovarian tissue samples using this techni-
que. This study identiﬁed genes whose expression pattern
distinguished between ovarian cancer of low and high malignancy
and ranked other genes in terms of the diagnostic potential of their
expression. Undoubtedly, the plethora of new candidate molecular
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Figure 6 Immunohistochemical localisation of hK6 in ovarian neoplasms of varying malignant potential, cell type and origin (epithelial vs mesenchymal).
(A) Invasive papillary serous adenocarcinoma. (B) Serous cystadenoﬁbroma. (C) Ovarian leiomyoma, a benign smooth muscle tumour. (D) Mucinous
epithelial tumour of low malignant potential.
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with, or determine the different biological properties and diverse
behaviour of, individual ovarian epithelial tumours. The goal for
clinical care is to select the battery of molecular markers that are
most informative in terms of unmasking the individual biological
proﬁle of each tumour, thereby laying out the molecular targets
for the most effective therapeutic intervention.
Recently we have found that hK6 is elevated in the serum of
a signiﬁcant number of women with ovarian cancer (Diamandis
et al, 2000e). Thus, hK6 may have diagnostic potential in addi-
tion to its prognostic signiﬁcance demonstrated in this study.
These ﬁndings warrant further basic and clinical studies to inves-
tigate the role of hK6 in ovarian cancer pathogenesis and
progression.
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